Skip to Content

Carlton Fields Attorney Gregory Boulos Authors Article About Cannabis Regulation
August 01, 2019
Carlton Fields attorney Gregory Boulos authored an article in the Cannabis Industry Journal about recent developments in regulation of cannabis products. The article, “CBD Health Claims Spur FDA Warning & Product Seizure Threats,” discusses the U.S. Food and Drug Administration’s recent warning letter to the CBD product company Curaleaf. The FDA questioned several of the company’s claims about its products’ effect on users’ health.
 
“Eliminating [regulatory] risks is impossible, but addressing them upfront before a product launch, regulatory crackdown, or lawsuit is considerably less expensive than dealing with costly litigation or government seizure of entire inventories,” Boulos wrote. “Developing in-depth institutional knowledge regarding the state-of-the-art scientific research on your product is a must.”
 
READ: Cannabis Industry Journal, “CBD Health Claims Spur FDA Warning & Product Seizure Threats”
Related Practices
Cannabis Law Mass Tort and Product Liability

Disclaimer

The information on this website is presented as a service for our clients and Internet users and is not intended to be legal advice, nor should you consider it as such. Although we welcome your inquiries, please keep in mind that merely contacting us will not establish an attorney-client relationship between us. Consequently, you should not convey any confidential information to us until a formal attorney-client relationship has been established. Please remember that electronic correspondence on the internet is not secure and that you should not include sensitive or confidential information in messages. With that in mind, we look forward to hearing from you.